Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is esta blished and square-wave meal bolus is used

Endocrine Practice

Volumn 15, Issue 3, 2009, Pages 229-233

  King, Allen B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Diabetes Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PRAMLINTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIET THERAPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NAUSEA; PATIENT MONITORING; PROSPECTIVE STUDY; SELF REPORT; WEIGHT REDUCTION;

EID: 67649218480     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.15.3.229     Document Type: Article

References (11)

1. Nyholm B, Orskov L, Hove KY, et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism. 1999;48:935-941.
2. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204-1212.
3. Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003;26:3074-3079.
4. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the longterm efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25:724-730.
5. Levetan C, Want LL, Weyer C, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003;26:1-8.
6. Edelman S, Garg S, Frias J, et al. A double-blind, placebo- controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29:2189-2195.
7. Kolterman OG, Schwartz S, Corder C, et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996;39:492-499.
8. King A, Armstrong D. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: bolus dosing. J Diabetes Sci Technol. 2007;1:42-46.
9. King A, Armstrong D. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: basal dosing. J Diabetes Sci Technol. 2007;1:36-41.
10. Bode BW. Insulin pump therapy. In: Lebovitz H, ed. Therapy for Diabetes Mellitus and Related Disorders. 4th ed. Alexandria, VA: American Diabetes Association, 2004: 224-231.
11. Davidson PC, Hebblewhite HR, Bode BW, et al. Statistically based CSII parameters: correction factor, CF (1700 rule), carbohydrate-to-insulin ratio, CIR (2.8 rule), and basal-to-total ratio. Diabetes Technol Ther. 2003;5: 237.